Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?

Paolo Cravedi, Varusca Brusegan, Piero Ruggenenti, Ruth Campbell, Giuseppe Remuzzi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalPharmaceuticals
Volume3
Issue number1
DOIs
Publication statusPublished - 2010

Fingerprint

Membranous Glomerulonephritis
Spironolactone
Nephrotic Syndrome
Peptidyl-Dipeptidase A
Blood Pressure
Enzyme Therapy
Proteinuria
Angiotensin-Converting Enzyme Inhibitors
Therapeutics

Keywords

  • Hyperkalemia
  • Idiopathic membranous nephropathy
  • Proteinuria
  • Spironolactone

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome : Does it really work? / Cravedi, Paolo; Brusegan, Varusca; Ruggenenti, Piero; Campbell, Ruth; Remuzzi, Giuseppe.

In: Pharmaceuticals, Vol. 3, No. 1, 2010, p. 1-9.

Research output: Contribution to journalArticle

@article{2f065818acd142afb44839020fe158d8,
title = "Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome: Does it really work?",
abstract = "We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure",
keywords = "Hyperkalemia, Idiopathic membranous nephropathy, Proteinuria, Spironolactone",
author = "Paolo Cravedi and Varusca Brusegan and Piero Ruggenenti and Ruth Campbell and Giuseppe Remuzzi",
year = "2010",
doi = "10.3390/ph3010001",
language = "English",
volume = "3",
pages = "1--9",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - Spironolactone plus full-dose ACE inhibition in patients with idiopathic membranous nephropathy and nephrotic syndrome

T2 - Does it really work?

AU - Cravedi, Paolo

AU - Brusegan, Varusca

AU - Ruggenenti, Piero

AU - Campbell, Ruth

AU - Remuzzi, Giuseppe

PY - 2010

Y1 - 2010

N2 - We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure

AB - We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and >3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to asystolic/diastolic blood pressure

KW - Hyperkalemia

KW - Idiopathic membranous nephropathy

KW - Proteinuria

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=77951926399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951926399&partnerID=8YFLogxK

U2 - 10.3390/ph3010001

DO - 10.3390/ph3010001

M3 - Article

AN - SCOPUS:77951926399

VL - 3

SP - 1

EP - 9

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 1

ER -